ClinicalTrials.gg

Program

ianalumab

Also written as “VAY736”, “Ianalumab” and “ianalumab s.c. q4w”.

In Novartis's pipeline, BAFF-R inhibitor, ADCC-mediated B-cell depletor. Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Lupus Erythematosus, Systemic · Sjogren's Syndrome · Lupus Nephritis · Arthritis, Rheumatoid, led by Novartis.

Furthest: phase 3, since Jul 12, 201734 company-led studies, 16 open or runningNext primary completion: Mar 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis3416 open or runningphase 3since Jul 12, 2017Aug 23, 2013Mar 26, 2027phase 3 · NCT05639114
  • Named in Novartis’s own pipeline as VAY736 (ianalumab), phase 4, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Aug 23, 2013.

  1. Nov 4, 20225 phase 3 studiesNCT05639114, NCT05624749, NCT05653349 and 2 more
  2. May 15, 2023Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT05885555 · 41 enrolled · United States, Argentina, Australia and more
  3. Aug 3, 2023Phase 3 study in Sjogren's SyndromeNCT05985915 · 612 enrolled · United States, Argentina, Australia and more
  4. Oct 2, 2023Phase 3 study in Lupus Erythematosus, SystemicNCT06133972 · 550 planned · United States, Argentina, Australia and more
  5. Feb 28, 2024Phase 2 study in Lupus Erythematosus, SystemicNCT06293365 · 155 enrolled · United States, Argentina, Canada and more
  6. May 8, 2024Phase 1 study in Lupus Erythematosus, SystemicNCT06411639
  7. Jun 17, 2024Phase 2 study in Scleroderma, DiffuseNCT06470048 · 203 enrolled · United States, Argentina, Austria and more
  8. Nov 11, 2024Phase 3 study in Lupus NephritisNCT06711887 · 348 planned · United States, Brazil, China and more
  9. May 5, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07039422
  10. Feb 12, 2026Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07421167 · 164 planned · United States
  11. May 26, 2026Phase 3 study in FatigueNCT07621809 · 570 planned · United States, Australia, Austria and more
  12. Jun 15, 2026Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07660172 · 36 planned
  13. Oct 1, 2026Primary completion moved from 2030-04-08 to 2034-04-03Date moved laterphase 3 · +48 months · NCT06133972
  14. Oct 15, 2026Phase 2 study withdrawnStudy stoppedNCT07039422 · “The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby redu…”

Ahead

  1. Mar 26, 2027Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT05639114
  2. Apr 12, 2027Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT05624749
  3. Jul 30, 2027Primary completion: phase 2 study in Scleroderma, DiffuseNCT06470048
  4. Sep 21, 2027Primary completion: phase 3 study in Lupus NephritisNCT05126277

TargetBeta

“BAFF-R inhibitor, ADCC-mediated B-cell depletor”the company's pipeline, read by Claude · source
“A fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 13C binding agent”ChEMBL 37, by rule

Other programs on TNFRSF13C

ProgramCompanyFurthest phaseStudies
Anti-BAFFR Monoclonal Antibody ESG206ruleshanghai-escugen-biotechnology-co-ltdphase 25
Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199ruleEli Lillyphase 11

Studies

All 34 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07660172Purpura, Thrombocytopenic, Idiopathic2Not yet recruitingApr 22, 203336
NCT07621809Fatigue · United States, Australia, Austria and more3RecruitingAug 15, 2029570
NCT07421167Purpura, Thrombocytopenic, Idiopathic · United States2RecruitingJan 18, 2029164
NCT07039422Purpura, Thrombocytopenic, Idiopathic2WithdrawnAug 30, 20300
NCT06711887Lupus Nephritis · United States, Brazil, China and more3RecruitingAug 1, 2035348
NCT06470048Scleroderma, Diffuse · United States, Argentina, Austria and more2Active, not recruitingJul 30, 2027203
NCT06411639Lupus Erythematosus, Systemic1WithdrawnDec 17, 20250
NCT06293365Lupus Erythematosus, Systemic · United States, Argentina, Canada and more2Active, not recruitingFeb 17, 2026155
NCT06133972Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3RecruitingApr 3, 2034550
NCT05985915Sjogren's Syndrome · United States, Argentina, Australia and more3Active, not recruitingApr 22, 2033612
NCT05885555Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more2Active, not recruitingFeb 5, 202541
NCT05653349Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more3Active, not recruitingOct 29, 2026226
NCT05653219Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Austria and more3Active, not recruitingJun 19, 2025152
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA) · United States, Argentina, Australia and more3Active, not recruitingFeb 20, 202690
NCT05624749Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3Active, not recruitingApr 12, 2027288
NCT05639114Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more3Active, not recruitingMar 26, 2027436
NCT05349214Sjogren's Syndrome · United States, Argentina, Australia and more3Active, not recruitingMay 13, 2025506
NCT05350072Sjogren's Syndrome · United States, Austria, Belgium and more3CompletedMay 7, 2025275
NCT05124925Sjogren's Syndrome · France2CompletedJun 26, 202421
NCT05126277Lupus Nephritis · United States, Argentina, Brazil and more3Active, not recruitingSep 21, 2027452
NCT04903197Lymphoma, Non-Hodgkin · Australia, China, Germany and more1TerminatedFeb 24, 202518
NCT03827798Hidradenitis Suppurativa · United States, Austria, Belgium and more2CompletedDec 4, 2024248
NCT03656562Lupus Erythematosus, Systemic · Argentina, Australia, China and more2CompletedJul 27, 2022107
NCT03574545Arthritis, Rheumatoid · Germany, Jordan1CompletedJul 18, 202448
NCT03400176Leukemia, Lymphocytic, Chronic, B-Cell · United States1TerminatedSep 29, 202339
NCT03287414Idiopathic Pulmonary Fibrosis · United States, Canada, Germany and more2TerminatedNov 25, 202030
NCT03217422Hepatitis, Autoimmune · United States, Argentina, Belgium and more3CompletedDec 28, 202368
NCT02962895Primary Sjogren Syndrome · United States, Argentina, Austria and more2CompletedJun 30, 2020190
NCT02675803Arthritis, Rheumatoid · Germany1CompletedJan 22, 201865
NCT02495129Sjogren's Syndrome2WithdrawnSep 20170
NCT02137889Recurrence · United States, Spain1TerminatedNov 20123
NCT02038049Multiple Sclerosis · United States, Czechia, Ukraine2TerminatedMay 5, 20158
NCT02149420Primary Sjögren's Syndrome · Germany2CompletedFeb 7, 201827
NCT01930175Pemphigus · United States, Austria, Bulgaria and more2TerminatedSep 25, 201913

How it is read

Names in the registry

  • “VAY736”, 15 entries
  • “Ianalumab”, 11 entries
  • “ianalumab”, 4 entries
  • “ianalumab s.c. q4w”, 1 entry
  • “ianalumab s.c. q12w”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.